002168SZSE

Announcement on Signing the Trademark License Agreement and Related Party Transaction

✨ AI Summary

Chongqing Huicheng Information Technology Co., Ltd. announces the signing of a trademark license agreement where its subsidiary, Ruien Xincheng, will receive royalty-free use of three trademarks from its related party, NGBiologics. This transaction is deemed a related party transaction and is expected to support the subsidiary's business development without negatively impacting the company's financial performance. The agreement has been approved by the independent directors and the board of directors.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_documentSign In to Upgrade

Huicheng Technology HI FUTURE Stock Code: 002168 Stock Abbreviation: ST Huicheng Announcement No.: 2026-033

Announcement on Signing the Trademark License Agreement and Related Party Transaction

The Company and the entire Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or significant omissions.

I. Overview of Related Party Transaction

  1. Recently, for the daily business operations of its holding subsidiary, Ruien Xincheng (Chongqing) Pharmaceutical Co., Ltd. (hereinafter referred to as "Ruien Xincheng"), Ruien Xincheng intends to sign a "Trademark License Agreement" with its related party, NGBiologics Technology Co., Ltd. (hereinafter referred to as "NGBiologics"). During the license period, NGBiologics agrees to grant Ruien Xincheng royalty-free use of the three trademarks it legally owns: "Aili," "Sailesi," and "Peitong." The scope of trademark authorization is limited to operations related to Aili®, Sailesi® Orlistat Capsules, and Peitong® Extended-Release Piniro Hydrochloride Tablets in Greater China.

  2. NGBiologics is a minority shareholder holding 49% of the equity in the Company's important holding subsidiary, Chongqing Ruien Pharmaceutical Co., Ltd. (hereinafter referred to as "Ruien Pharmaceutical"). NGBiologics and its related parties under common control have business dealings with Ruien Pharmaceutical, and the transaction amounts are relatively high, which can significantly influence the business development of Ruien Pharmaceutical. In accordance with the "Shenzhen Stock Exchange Stock Listing Rules," "Accounting Standards for Business Enterprises No. 36—Related Party Disclosures," and other relevant regulations, based on the principle of prudence, the Company has identified NGBiologics and its related parties under common control as related legal persons of the Company since the day after the disclosure of the 2025 annual report (i.e., April 1, 2026). This transaction constitutes a related party transaction as defined by the "Shenzhen Stock Exchange Stock Listing Rules" and the "Shenzhen Stock Exchange Listed Company Self-Regulation Guidelines No. 7—Transactions and Related Party Transactions."

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.

Notes & Comments

Sign in to leave a comment or private note.

Loading…